Morepen Labs Files FY26 Compliance Report Amid Share Cancellation Roadblock

Morepen Laboratories Limited has submitted its Annual Secretarial Compliance Report for the financial year ending March 31, 2026. The report, prepared by Practicing Company Secretaries PD & Associates, confirms the company's adherence to various SEBI regulations.

However, the filing also highlighted significant challenges with the company's capital reduction plan. Stock exchanges have refused the application for the cancellation of 5,062,872 equity shares. This refusal stems from non-compliance with the terms stipulated in an order from NCLT Chandigarh.

This situation represents a regulatory obstacle for Morepen Labs' capital restructuring efforts. Delays and refusals from stock exchanges can affect investor confidence and introduce uncertainty around the execution of corporate actions like capital reduction.

Previously, Morepen Laboratories had secured approval from the National Company Law Tribunal (NCLT) Chandigarh for a capital reduction scheme involving the cancellation of approximately 50.62 lakh equity shares. Following NCLT approval, the company had applied to the stock exchanges for the listing and alignment of these cancelled shares.

Consequently, shareholders face continued uncertainty regarding the completion of the capital reduction. The company must now navigate a complex regulatory path involving both the NCLT and SEBI. Management's ability to resolve the compliance discrepancy will be crucial for the finalization of the share cancellation, likely requiring fresh applications to SEBI.

Potential risks include further delays or outright refusal from SEBI or stock exchanges on new applications. The company may also incur increased costs associated with reapplying and addressing the compliance gap. Inefficient resolution could also damage the company's reputation and affect investor perception.

This compliance issue arises within the broader pharmaceutical sector, where companies such as Sun Pharmaceutical Industries and Dr. Reddy's Laboratories operate under stringent regulatory frameworks. However, capital reduction issues are specific to corporate actions rather than daily operations.

In separate developments, Morepen Laboratories reported a net profit of Rs 50 crore for Q3 FY24, a 22.4% year-on-year increase. The company also secured USFDA approval for its API plant in May 2025 and entered a pact with South Korea's KGC for medical devices in January 2024.

Looking ahead, investors will monitor management's progress in addressing the compliance gap between NCLT terms and exchange requirements. Key factors to watch include the timeline for submitting fresh applications to SEBI and stock exchanges, any further company communications on the share cancellation issue, and overall investor sentiment.